- 1 Facing the Omicron variant – How well do vaccines protect against mild and severe
- 2 COVID-19? Third interim analysis of a living systematic review
- 3 Wiebe Külper-Schiek^{1†}, Vanessa Piechotta^{1†}, Antonia Pilic¹, Madeleine Batke¹, Léa-
- 4 Sophie Dreveton¹, Brogan Geurts², Judith Koch¹, Stefan Köppe¹, Marina Treskova^{1,3},
- Sabine Vygen-Bonnet¹, Maria Waize¹, Ole Wichmann¹, Thomas Harder¹ 5
- 6 ¹ Department of Infectious Disease Epidemiology, Robert Koch Institute, Berlin, Germany
- 7 ² Centre for International Health Protection, Robert Koch Institute, Berlin, Germany
- 8 ³ Institute of Global Health, Heidelberg University Hospital, Heidelberg, Germany
- 9 † these authors have contributed equally to this work and share first authorship
- 10 Keywords: SARS-CoV-21; systematic review2; vaccine effectiveness3; vaccination4;
- 11 COVID-195; Omicron variant6; variant of concern7.
- 12 **Abstract**
- 13 **Background:**
- The SARS-CoV-2 Omicron variant is currently the dominant variant globally. This 3rd interim 14
- 15 analysis of a living systematic review summarizes evidence on COVID-19 vaccine
- 16 effectiveness (VE) and duration of protection against Omicron.
- 17 **Methods:**
- We systematically searched the COVID-19 literature for controlled studies evaluating the 18
- 19 effectiveness of COVID-19 vaccines approved in the European Union up to 14/01/2022,
- 20 complemented by hand-searches of websites and metasearch engines up to 11/02/2022. We
- 21 considered the following comparisons: full primary immunization vs. no vaccination; booster
- 22 immunization vs. no vaccination; booster vs. primary immunization. VE against any confirmed
- SARS-CoV-2 infection, symptomatic, and severe COVID-19 (i.e. COVID-19-related 23
- 24 hospitalization, ICU-admission, or death) was indicated providing estimate ranges. Meta-
- 25 analysis was not performed due to high study heterogeneity. Risk of bias was assessed with
- 26 ROBINS-I, certainty of evidence evaluated using GRADE.
- 27 **Results:**
- 28 We identified 26 studies, including 430 to 2.2 million participants.
- 29 VE against any confirmed SARS-CoV-2 infection compared to no vaccination ranged between
- 30 0-62% after full primary immunization, and between 34-66% after a booster dose. VE-range
- 31 for booster vs. primary immunization was 34-54.6%.
- 32 Against symptomatic COVID-19, VE ranged between 6-76% after full primary immunization,
- 33 and between 19-73.9% after booster immunization, if compared to no vaccination. When
- 34 comparing booster vs. primary immunization VE ranged between 56-69%.
- 35 VE against severe COVID-19 compared to no vaccination ranged between 3-84% after full
- primary immunization, and between 12-100% after a booster dose. One study compared booster 36
- vs. primary immunization (VE 100%, 95% CI 71.4-100).

 NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice. 37

- 38 VE was characterized by a moderate to strong decline within three to six months for SARS-
- 39 CoV-2 infections and symptomatic COVID-19. Against severe COVID-19 protection remained
- 40 robust at least for up to six months. Waning immunity was more profound after primary than
- 41 booster immunization.
- 42 Risk of bias was moderate to critical across studies and outcomes. GRADE-certainty was very
- 43 low for all outcomes.

- 44 Author's conclusions:
- 45 Under the Omicron variant, effectiveness of EU-licensed COVID-19 vaccines in preventing
- any SARS-CoV-2 infection or mild disease is low and only short-lasting after primary
- 47 immunization, but can be improved by booster vaccination. VE against severe COVID-19
- 48 remains high and is long-lasting, especially after receiving the booster vaccination.

1 Introduction

50

68

69

70

- 51 The Omicron variant of SARS-CoV-2 (Phylogenetic Assignment of Named Global Outbreak
- 52 (Pango) lineage designation B.1.1.529) was first detected in South-Africa in November 2021.
- 53 Since then, the variant spread rapidly across countries and has largely replaced all other variants
- 54 globally (>99,8% of all sequences submitted to the Global Initiative on Sharing All Influenza
- 55 Data (GISAID) were Omicron in week 5 of 2022) (1). Evidence suggests that the Omicron
- variant has a growth rate advantage compared to the previously dominant Delta variant, leading
- 57 to its overtake as the dominant variant globally, while the Delta variant now only represents
- 58 0.1% of collected samples (1).
- 59 High rates of asymptomatic infection and symptomatic COVID-19 disease among people
- 60 previously infected with SARS-CoV-2 or fully vaccinated with a COVID-19 vaccine raise
- 61 concerns that the currently available vaccines are less or no-longer effective against the
- Omicron variant. To summarize the existing evidence on the effectiveness and the duration of
- 63 protection confered by COVID-19 vaccines licensed in the European Union (EU) with respect
- 64 to the Omicron variant, and compare it to the Delta variant, we synthesized the evidence within
- an ongoing living systematic review (LSR), conducted by Robert Koch Institute (RKI) in
- 66 collaboration with the National Immunisation Technical Advisory Groups (NITAGs) network
- 67 coordinated by the European Centre for Disease Prevention and Control (ECDC) (2).

2 Methods

Literature search

- 71 The LSR follows the Preferred Reporting Items for Systematic Review and Meta-Analysis
- 72 (PRISMA) guideline (supplement material 1, part 1), and was registered in the *Prospective*
- 73 Register of Systematic Reviews (PROSPERO registration ID: CRD42020208935; updated on:
- 74 09 March 2022). All amendments since initial registration are available online. The methods
- have been previously described in detail (2). In brief, we included studies of any design that
- 76 had a comparison group and investigated vaccine effectiveness (VE) against SARS-CoV-2
- infection of any severity of COVID-19 vaccines approved by the European Medicine Agency
- 78 (EMA) in people ≥12 years of age (see supplement material 1, part 2 for complete PICO
- question). For this 3rd update of the LSR, we only considered studies that reported on outcomes
- 80 that are due to the SARS-CoV-2 Omicron variant or that occurred during a dominant circulation
- of the Omicron variant. There were no restrictions with regard to publication language or status.
- We searched the COVID-19 literature database constructed by the RKI library (see (2) and
- 83 **supplement material 1, part 3** for description of the database and the search strategy) for
- 84 studies published between 23 October 2021 and 14 January 2022. We added literature identified
- by hand-search of websites and metasearch engines indicated in **supplement material 1**, part
- 86 3 up to 11 February 2022. Potentially relevant publications were screened at title/abstract and
- 87 full-text level by pairs of independent investigators (AP, SK, MB, LSD, VP and/or WKS). Data
- 88 from included studies (see PROSPERO registration for details) was extracted in duplicate and
- summarized in tables (AP, MB, VP, WKS). We considered VE data on the following three
- comparisons by vaccine type (mRNA-based, vector-based, heterologous scheme, any vaccine):
- 1. completed primary immunization vs. no vaccination (i.e., placebo, no vaccination, or vaccine not directed against COVID-19), 2. booster immunization vs. no vaccination, 3. booster
- 93 immunization vs. primary immunization. Outcomes of interest were VE against polymerase
- 94 chain reaction- (PCR) or antigen-test confirmed SARS-CoV-2 infection of "any type" (i.e.
- 95 studies did not indicate underlying symptoms), "symptomatic COVID-19", and "severe
 - 3

COVID-19" (including hospitalization, ICU-admission, or death due to SARS-CoV-2 infection). To investigate VE at different time points since vaccination, data was stratified into four time periods (\approx 14 days, > 14 days up to 3 months, > 3 months up to 6 months, > 6 months). As there was substantial heterogeneity across studies, we abstained from conducting a metaanalysis, but summarized the studies as follows: We assessed the range of VE of any, mRNAor vector-based vaccines or for heterologous schedules against the outcomes described for the different time strata by including VE estimates from all studies that provide VE estimates for the respective time point (supplement material, part 4). If studies reported VE data for more granular time points within the defined time stratum, it was always the estimate of the latest time point within the stratum that contributed to the indicated range (e.g. if studies reported VE after 2-4 and 5-9 weeks after vaccination, the estimate of 5-9 weeks was included in the depicted effect range). Only for the time stratum "≈14 days", VE estimates closest to 14 days were included. The latter stratum included furthermore VE data that was only assessed at "≥14 days" after primary vaccination, ">7 days" post booster vaccination or when the time point of assessment after primary immunization was not reported at all. To visualize VE over time after primary and booster vaccination the estimates contributing to the VE range for the respective time category were included in forest plots. Additionally, we assessed the percentage difference of VE over time in studies reporting VE estimates for at least two different time points. We provide the range of observed minimal and maximal differences across studies. For detailed information we refer to the table of all extracted information provided in Appendix 2. ROBINS-I was used to assess risk of bias (3). The certainty of the evidence included in the LSR was rated using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach (4, 5).

3 Results

96 97

98

99

100 101

102

103

104

105

106

107 108

109

110

111

112

113

114

115

116

117

118

119

120

129

121 Study screening

- We identified a total of 8,428 entries in the database until 14 January 2022. Another 38
- potentially relevant studies were added by hand-search until 11 February 2022. After
- title/abstract and full-text screening, data from 26 studies (6-31) were extracted (supplement
- material 1, part 4; figure 1). If studies referred to previously published references for further
- information, these references were considered and information extracted if necessary. For pre-
- print studies with several versions available, the most recent update published until 11 February
- 128 2022 was included.

Characteristics of included studies

- The included studies, of which most (21/26) were not yet peer-reviewed, reported VE estimates
- against infections (and related outcomes) with only the Omicron variant (5/26) or included VE
- data against infections with the Delta variant for comparison (21/26). Fourteen studies assessed
- VE using a test-negative design, eight based on a cohort design, three on a case-control design
- and one study reported infection rates per vaccination status within a transmission study.
- In the studies the SARS-CoV-2 variant causing the investigated outcome was identified either
- from time periods with known dominant circulation of the Omicron (resp. Delta) variant in the
- corresponding study location, from whole-genome sequencing (WGS), or through S-gene target
- failure (SGTF) in PCR assays. Studies using the latter method subdivided the SARS-CoV-2
- positive samples by the detection or non-detection of the S-gene in a three gene PCR assay. As
- the SGTF is characteristic for the Omicron variant, but rare in the Delta variant, studies used

- the detection of the S-gene as a proxy for the Delta variant, and the "non-detection" as a proxy
- 142 for the Omicron variant. As most studies report overall VE estimates without further
- differentiating between WGS- or SGTF-variant assessment the data was synthesized only into
- "dominance" and "sequencing/SGTF".
- 145 Studies were conducted in ten different countries and mainly used national electronic registries
- or claims data from the general population for laboratory, immunization and patient
- 147 characteristics. Only three studies investigated VE for specific populations such as in health
- care workers, veterans or patients under hemodialysis therapy. Minimum age of included study
- participants was 12 years (if reported). However, none of the studies provided subgroup data
- 150 for children or adolescents.
- 151 Twenty-two studies reported VE estimates for full primary immunization (as defined per study),
- 152 23 for a booster dose (additional dose after full primary immunization). One of the latter studies
- 153 compared the effect of a second booster dose (fourth doses) with a single booster dose. VE-
- estimates for several time points after full primary immunization have been reported by eleven
- studies, eight studies reported VE data for several time points after booster immunization.
- 156 Most studies investigated VE of mRNA-based vaccines (13 on Comirnaty, nine on Spikevax),
- seven studies reported VE for vector-based vaccines (four on Vaxzevria, three on COVID-19
- vaccines from Janssen) and seven studies did not differentiate VE per vaccine. None of the
- studies provided data for Nuvaxovid.

160 Prevention of infection with SARS-CoV-2 Omicron variant (without differentiation

- between asymptomatic or symptomatic cases)
- 162 Twelve studies (including between 1,220 and 2.2 million participants) reported the
- effectiveness of COVID-19 vaccines in preventing infection of any type with SARS-CoV-2
- Omicron variant (without differentiation between asymptomatic or symptomatic cases). After
- 165 full primary immunization VE across all studies ranged between 0 and 62% at "≈14 days" post
- vaccination, compared to no vaccination. For the time-periods ">14 days up to 3 months", ">3
- months up to 6 months" and ">6 months" after vaccination VE-ranges, assessed across all
- reported VE estimates, were 4.2 to 42.8%, 0 to 23% and 0 to 8.6%, respectively (table 1, figure
- 2). The data from the two studies reporting VE for at least two time points show a decline of
- 170 VE between >14 days to up to 6 months by 16 to 34% after vaccination with mRNA-based
- vaccines (figure 2) (7, 14). As there was no VE data over time identified for vector-based
- vaccines, unspecified vaccine or heterologous schedules respective VE decline could not be
- assessed.

184

- 174 After booster vaccination, VE estimates at "≈14 days" post vaccination across all studies ranged
- between 34 and 76%, compared to no vaccination, and between 14 and 53%, compared to full
- primary immunization (12, 21). Follow-up data were insufficient to evaluate waning of
- immunity after booster vaccination.
- 178 The study investigating VE of four vs. three doses of mRNA-based vaccines reported VE
- estimate of 47% (95% CI 44-47) against Omicron infection at 12 or more days after the fourth
- dose (29). VE ranges against infection with the Delta variant for the different time points are
- provided in **supplement material 1**, part 5.
- 182 Risk of bias was serious to critical for all assessed studies (see **figure 3**). Key concern was no
- or insufficient adjustment for confounders.

Prevention of symptomatic COVID-19

- Seven studies, including between 430 and 2.2 million participants, estimated the effectiveness of COVID-19 vaccines in preventing symptomatic infection with the SARS-CoV-2 Omicron variant (**supplement material 1, part 4**). Compared to unvaccinated individuals, VE at ≈14 days after vaccination summarized from all studies reporting on this time point ranged between 6 and 76%. For the time-period ">14 days up to 3 months", ">3 months up to 6 months" and ">6 months" VE ranges were 12-54%, 6.1-20.8%, and 0-13%, respectively. VE estimates from studies that report data for at least two time points suggest a decrease in protective immunity
- against symptomatic COVID-19 between 45-63% for mRNA-based vaccine recipients, and of 50% for vector-based vaccine recipients over the time period >14 days up to >6 months after
- 194 vaccination (**figure 4**, (8, 25)).

206

- After booster vaccination, VE against symptomatic infection ranged between 19 and 73.9% at "≈14 days" post vaccination, compared to no vaccination, and between 50 to 68%, compared to primary vaccination (6, 9). For the time point ">14 days up to 3 months" estimates were only
- reported for the comparison with no vaccination and ranged between 43.7 and 65.4%. No study
- reported VE for later observation periods. The two studies that provide data for both these time periods show a 9-28% decrease in VE after booster vaccination with a mRNA-based vaccine
- and between 32-34% after heterologous vaccination schemes (**figure 4** (8, 25)). However, 95%
- 202 confidence intervals between observation periods were partially overlapping.
- Risk of bias was serious to critical for all but one of the assessed studies (see **figure 5**). The
- remaining study was rated to have a moderate risk. All factors considered relevant for
- 205 confounding were taken into account, however residual confounding could not be ruled out.

Prevention of severe COVID-19 (hospitalization, ICU-admission, or death)

- VE against severe COVID-19 was assessed in seventeen studies including 1,220 to 2.2 million
- 208 participants (supplement material 1, part 4). VE estimates in primary vaccinated compared
- 209 to unvaccinated individuals ranged from 3 to 84% at "≈14 days" post vaccination, between 21
- and 95% at ">14 days up to 3 months", between 0 and 91% at ">3 months up to 6 months" and
- between 32.7 and 86% at ">6 months" after vaccination. Studies reporting VE for at least two
- 212 time points indicate a decline by up to 40% for mRNA-based vaccines, and 15-67% for vector-
- based vaccines between 14 days and ≥ 6 months after vaccination (see figure 6) (8, 20).
- However, 95% confidence intervals were wide and overlapping across time points. One study
- 215 reported no difference in the first and last time point estimate (17), and another study reported
- 216 a small non-significant increase (VE at 30-180 days: 73.7% (95% CI 46.8-87); VE at ≥210
- 217 days: 80.7% (95% CI 71.3-87); (25)) (supplement material 2).
- For booster vaccinated compared to unvaccinated individuals VE ranged from 12 to 100% at
- 219 "≈14 days" post vaccination and between 78 and 93.7% at ">14 days up to 3 months".
- According to three studies, VE after booster vaccination remained stable over this time period
- 221 (17, 20, 25), irrespective of the vaccine or scheme used (mRNA-, vector-based or heterologous
- vaccination). Only one study showed a decline of VE of approximately 12% over the respective
- 223 time period after mRNA-based vaccination (8). VE data was not available for later time periods.
- For the comparison against full primary immunization we calculated VE of booster vaccination
- against severe disease based on data from one study (6) that only reported data for 7 days after
- 226 booster vaccination (VE: 100% (95% CI 71.4-100)).
- The study assessing the effect of a fourth vs. a third mRNA-based vaccine dose reported VE
- against severe disease of 75% (95% CI 57-86) at ≥12 days after additional booster vaccination
- 229 (29). Data to assess duration of protection was not available.

- In all but one studies risk of bias was serious to critical (see **figure 7**). The remaining study was
- rated to have a moderate risk due to the potential for residual confounding.

232 Effectiveness against the Omicron variant, compared to the Delta variant

- 233 Twenty-one studies reported VE estimates both against infections with the Omicron and with
- 234 the Delta variant (supplement material 1, part 4; supplement material 1, part 5;
- supplement material 2).
- 236 In addition to our PICO question, we included eight studies that estimated risk reduction of
- 237 infections with the Omicron variant compared to those with the Delta variant. Risk ratios from
- 238 these studies suggest that the risk for any type of SARS-CoV-2 infection and symptomatic
- 239 COVID-19 despite vaccination is higher for the Omicron variant than for the Delta variant.
- 240 Instead, risk of severe disease is lower in vaccinated people infected with the Omicron variant
- compared to those vaccinated and infected with the Delta variant (supplement material 1, part
- 242 **6 and 7**).

243 **Publication bias**

- 244 Potential publication bias could not be explored through statistical testing and generating funnel
- plots, as none of the comparisons/outcomes/time points involved sufficient studies.

246 GRADE

249

250

- Overall, GRADE-certainty of evidence is very low for all outcomes, due to the underlying study
- 248 limitations and serious heterogeneity.

4 Discussion

- 251 This 3rd update of our LSR provides evidence on VE and duration of protection of EU-approved
- 252 COVID-19 vaccines against any type of infection, symptomatic infection, and COVID-19
- associated severe disease (i.e. hospitalization, ICU admission, or death) caused by the SARS-
- 254 CoV-2 Omicron variant.
- 255 Though evidence is uncertain about the exact level of protection against all investigated
- outcomes, both after primary and after a booster vaccination, data suggest that VE was higher
- 257 after booster when compared to primary immunization. Results suggest a rapid decline of
- 258 vaccine-induced protection after completion of the primary vaccination series. The effect is
- profound for infections of any type, but less pronounced for severe disease. This is in line with
- 260 the findings of a recently published meta-regression analysis on pre-Omicron variants (32). VE
- 261 could be restored to high levels of protection by the booster dose, though first follow-up data
- do also suggest a waning effect (8, 19, 25). However, VE against severe disease caused by
- 263 Omicron remained high for at least 3 months post booster immunization (no data for longer
- follow-up available). Compared to VE against the Delta variant, vaccines were less effective
- for all reported outcomes.
- 266 In the light of the more transmissible Omicron variant and the advancing immunization
- 267 campaigns across countries, evidence on the need and the timing of booster vaccination is of
- 268 increasing public health interest. Thus, we decided to adapt our PICO questions and inclusion
- 269 criteria and considered also studies that compare booster vaccinated individuals with primary
- vaccinated ones. The effect of waning immunity was assessed through stratifying VE data into
- 271 multiple observation periods.

As included studies were highly heterogenous (e.g. in terms of analyzed time point after vaccination, study population, applied vaccine schedules, if reported at all) and had serious to critical risk of bias, we decided not to perform meta-analyses, but provide ranges of reported VE estimates across studies to increase transparency and prevent misinterpretation. As studies assessed VE inconsistently for different time points or periods, a standardized assessment for time points of VE evaluation, as suggested by WHO (33), would facilitate the comparison of evidence across studies and better allow a synthesis of the evidence.

Most studies included here used the test-negative design. This study design was initially introduced to estimate VE against seasonal influenza, and thought to control for differences in seeking medical care (34). In the COVID-19 era, the test-negative studies might be prone to bias caused by specific testing strategies or behaviors at the study location. However, those are mainly not reported in the studies, making it difficult to interpret reported estimates, when individuals are not tested due to underlying symptoms. Most studies did not indicate the vaccination schedule applied for full primary immunization or the booster dose. For immunocompromised people a three-dose primary vaccination schedule is recommended by the WHO Strategic Advisory Group of Experts on Immunization to improve immune response. As this recommendation is implemented in many countries¹, it is possible that VE estimates for a booster schedule include those that received a 3rd doses within an "optimized" schedule for immunocompromised people.

This 3rd update provides a comprehensive overview of the currently available evidence on VE against infection with the SARS-CoV-2 Omicron variant. We provide an in-depth analysis of the VE estimates extracted from the included studies that were identified following a pre-registered protocol. We conducted thorough risk of bias assessment of the studies, and evaluated the certainty of evidence using the GRADE approach.

Due to the highly dynamic publication landscape in this field, additional studies have been published since our last search that are not captured by this analysis. In fact, we are aware of at least two studies reporting on adolescents, which were published after our data cut (35, 36). As in adults, lower VE against infections and severe disease were observed for the Omicron variant, when compared to the Delta variant. However, data on duration of protection are contradicting. While one study reported a decrease in VE against hospitalizations by 6-19% at more than 5 months after primary immunization (35). The second study did not identify a decrease in VE against any infections but was based only on few events (36). In addition to studies not included as they were published after our final search date, we noticed that some studies updated data on preprint servers after initial publication including data on longer followup periods. We therefore cannot exclude that authors revised the available pre-print versions including additional data after we completed data extraction for this update. Further, we cannot exclude a risk of potential bias as real-life observation are based on retrospective analyses which are not systematically registered. Thus, intent and possibility of publication might depend on observed results. However, due to the increase of publications on pre-print servers, the risk of publication bias is probably low.

Additional data limitations stem from the fact that VE estimates for more than one vaccine were reported.

¹ An additional dose is recommended for immunocompromised people in all eight countries where included

5 Conclusion

- 317 Current evidence suggests that the effectiveness of COVID-19 vaccines licensed in the EU is
- 318 low after primary vaccination, and improved after booster vaccination in preventing infections
- 319 with the SARS-CoV-2 Omicron variant. For both primary and booster immunization it is
- 320 characterized by a rapid decrease over time. VE against severe courses of COVID-19 remains
- 321 generally high.

316

327

328

331

332

- 322 Studies included in this update were very heterogenous, therefore, pooling of estimates was not
- 323 appropriate. To allow statistical synthesizes of effects, studies need to be comparable for
- 324 clinical and meta-epidemiological aspects. Thus, certain standards for VE studies, as suggested
- by WHO, are useful to better inform vaccination guidelines and reliably assess the public health
- impact of vaccination campaigns.

6 Conflict of Interest

- 329 The authors declare that the research was conducted in the absence of any commercial or
- financial relationships that could be construed as a potential conflict of interest.

7 Author Contributions

- WKS was first and second reviewer, responsible for data extraction, performed bias assessment
- and drafted the manuscript. VP was first and second reviewer, responsible for data extraction,
- performed bias assessment, conducted GRADE assessment and contributed to the manuscript.
- 336 AP was first and second reviewer, responsible for data extraction, performed bias assessment
- and contributed to the manuscript. MB was first reviewer, responsible for data extraction,
- performed bias assessment and contributed to the manuscript. MW, SK, LSD and BG were first
- reviewers and contributed to the manuscript. MT provided input into the interpretation of the
- results and developed forest plots. SVB and JK contributed to the manuscript. OW held general
- oversight of the conducted work and revised the manuscript. TH conceived the study and
- 342 contributed to the manuscript. All authors contributed to the interpretation of the data and
- provided important intellectual content to the manuscript.

345 8 Funding

346 None.

344

347

348

9 Acknowledgements

- We sincerely thank the authors of Andrews et al. and Kahn et al. for providing us with
- 350 additional data.

References

- 352 1. World Health Organization. Weekly epidemiological update on COVID-19 22
- March 2022 https://www.who.int/publications/m/item/weekly-epidemiological-update-on-
- 354 covid-19---22-march-20222022 [
- 355 2. Harder T, Koch J, Vygen-Bonnet S, Kulper-Schiek W, Pilic A, Reda S, et al. Efficacy
- and effectiveness of COVID-19 vaccines against SARS-CoV-2 infection: interim results of a
- living systematic review, 1 January to 14 May 2021. Euro Surveill. 2021;26(28).
- 358 3. Sterne JA, Hernán MA, Reeves BC, Savović J, Berkman ND, Viswanathan M, et al.
- ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ.
- 360 2016;355:i4919.
- 361 4. Guyatt G, Oxman AD, Akl EA, Kunz R, Vist G, Brozek J, et al. GRADE guidelines:
- 1. Introduction-GRADE evidence profiles and summary of findings tables. Journal of clinical epidemiology. 2011;64(4):383-94.
- 364 5. Schünemann HJ, Cuello C, Akl EA, Mustafa RA, Meerpohl JJ, Thayer K, et al.
- 365 GRADE guidelines: 18. How ROBINS-I and other tools to assess risk of bias in
- nonrandomized studies should be used to rate the certainty of a body of evidence. Journal of clinical epidemiology. 2019;111:105-14.
- 368 6. Abu-Raddad LJ, Chemaitelly H, Ayoub HH, AlMukdad S, Tang P, Hasan MR, et al.
- 369 Effectiveness of BNT162b2 and mRNA-1273 COVID-19 boosters against SARS-CoV-2
- 370 Omicron (B.1.1.529) infection in Qatar. medRxiv. 2022.
- 7. Hansen CH, Schelde AB, Moustsen-Helm IR, Emborg H-D, Krause TG, Mølbak K, et
- al. Vaccine effectiveness against SARS-CoV-2 infection with the Omicron or Delta variants
- following a two-dose or booster BNT162b2 or mRNA-1273 vaccination series: A Danish
- 374 cohort study. medRxiv. 2021.
- 375 8. UK Health Security Agency. COVID-19 vaccine surveillance report week 4
- 376 https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment data/
- 377 file/1050721/Vaccine-surveillance-report-week-4.pdf2022 [updated January 27, 2022.
- 378 9. Accorsi EK, Britton A, Fleming-Dutra KE, Smith ZR, Shang N, Derado G, et al.
- 379 Association Between 3 Doses of mRNA COVID-19 Vaccine and Symptomatic Infection
- 380 Caused by the SARS-CoV-2 Omicron and Delta Variants. JAMA. 2022;327(7):639-51.
- 381 10. Young-Xu Y. Effectiveness of mRNA COVID-19 Vaccines against Omicron among
- 382 Veterans. medRxiv. 2022.
- 383 11. Buchan SA, Chung H, Brown KA, Austin PC, Fell DB, Gubbay JB, et al.
- 384 Effectiveness of COVID-19 vaccines against Omicron or Delta symptomatic infection and
- severe outcomes. medRxiv. 2022.
- Lyngse FP, Mortensen LH, Denwood MJ, Christiansen LE, Møller CH, Skov RL, et
- al. SARS-CoV-2 Omicron VOC Transmission in Danish Households. medRxiv. 2021.
- 388 13. Sheikh A, Kerr S, Woolhouse M, McMenamin J, Robertson C. Severity of Omicron
- variant of concern and vaccine effectiveness against symptomatic disease: national cohort
- with nested test negative design study in Scotland
- 391 https://www.research.ed.ac.uk/en/publications/severity-of-omicron-variant-of-concern-and-
- 392 vaccine-effectiveness-: Edinburgh Research Explorer; 2021 [updated December 22, 2021.
- 393 14. Tseng HF, Ackerson BK, Luo Y, Sy LS, Talarico CA, Tian Y, et al. Effectiveness of
- 394 mRNA-1273 against SARS-CoV-2 omicron and delta variants. medRxiv. 2022.
- 395 15. Thompson MG, Natarajan K, Irving SA, Rowley EA, Griggs EP, Gaglani M, et al.
- 396 Effectiveness of a Third Dose of mRNA Vaccines Against COVID-19-Associated Emergency
- 397 Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods
- 398 of Delta and Omicron Variant Predominance VISION Network, 10 States, August 2021-
- January 2022. MMWR Morbidity and mortality weekly report. 2022;71(4):139-45.

- 400 16. Willett BJ, Grove J, MacLean OA, Wilkie C, Logan N, Lorenzo GD, et al. The hyper-
- 401 transmissible SARS-CoV-2 Omicron variant exhibits significant antigenic change, vaccine
- 402 escape and a switch in cell entry mechanism. medRxiv. 2022.
- 403 17. Tartof SY, Slezak JM, Puzniak L, Hong V, Xie F, Ackerson BK, et al. BNT162b2
- 404 (Pfizer-Biontech) mRNA COVID-19 Vaccine Against Omicron-Related Hospital and
- Emergency Department Admission in a Large US Health System: A Test-Negative Design.
- 406 2022.
- 407 18. Jalali N, Brustad HK, Frigessi A, MacDonald E, Meijerink H, Feruglio S, et al.
- 408 Increased household transmission and immune escape of the SARS-CoV-2 Omicron variant
- 409 compared to the Delta variant: evidence from Norwegian contact tracing and vaccination data.
- 410 medRxiv. 2022.
- 411 19. Lauring AS, Tenforde MW, Chappell JD, Gaglani M, Ginde AA, McNeal T, et al.
- 412 Clinical Severity and mRNA Vaccine Effectiveness for Omicron, Delta, and Alpha SARS-
- 413 CoV-2 Variants in the United States: A Prospective Observational Study. medRxiv. 2022.
- 414 20. Nyberg T, Ferguson N, Nash S, Webster H, Flaxman S, Andrews N, et al.
- 415 Comparative Analysis of the Risks of Hospitalisation and Death Associated with SARS-CoV-
- 416 2 Omicron (B.1.1.529) and Delta (B.1.617.2) Variants in England. SSRN. 2022.
- 417 21. Andeweg SP, de Gier B, Eggink D, van den Ende C, van Maarseveen N, Ali L, et al.
- 418 Protection of COVID-19 vaccination and previous infection against Omicron BA.1 and Delta
- 419 SARS-CoV-2 infections, the Netherlands, 22 November 2021- 19 January 2022. medRxiv.
- 420 2022.
- 421 22. Gray GE, Collie S, Garrett N, Goga A, Champion J, Zylstra M, et al. Vaccine
- 422 effectiveness against hospital admission in South African health care workers who received a
- 423 homologous booster of Ad26.COV2 during an Omicron COVID19 wave: Preliminary Results
- 424 of the Sisonke 2 Study. medRxiv. 2021.
- 425 23. Veneti L, Bøås H, Bråthen Kristoffersen A, Stålcrantz J, Bragstad K, Hungnes O, et al.
- 426 Reduced risk of hospitalisation among reported COVID-19 cases infected with the SARS-
- 427 CoV-2 Omicron BA.1 variant compared with the Delta variant, Norway, December 2021 to
- 428 January 2022. Eurosurveillance. 2022;27(4):2200077.
- 429 24. Spensley K, Gleeson S, Martin P, Thomson T, Clarke CL, Pickard G, et al.
- Comparison of vaccine effectiveness against the Omicron (B.1.1.529) variant in patients
- 431 receiving haemodialysis. medRxiv. 2022.
- 432 25. Chemaitelly H, Ayoub HH, AlMukdad S, Tang P, Hasan MR, Yassine HM, et al.
- Duration of protection of BNT162b2 and mRNA-1273 COVID-19 vaccines against
- 434 symptomatic SARS-CoV-2 Omicron infection in Qatar. medRxiv. 2022.
- 435 26. Nunes MC, Sibanda S, Baillie VL, Kwatra G, Aguas R, Madhi SA, et al. SARS-CoV-
- 2 Omicron symptomatic infections in previously infected or vaccinated South African
- 437 healthcare workers. medRxiv. 2022.
- 438 27. Collie S, Champion J, Moultrie H, Bekker L-G, Gray G. Effectiveness of BNT162b2
- 439 Vaccine against Omicron Variant in South Africa. New England Journal of Medicine.
- 440 2021;386(5):494-6.
- Lewnard JA, Hong VX, Patel MM, Kahn R, Lipsitch M, Tartof SY. Clinical outcomes
- among patients infected with Omicron (B.1.1.529) SARS-CoV-2 variant in southern
- 443 California. medRxiv. 2022.
- 444 29. Bar-On YM, Goldberg Y, Mandel M, Bodenheimer O, Amir O, Freedman L, et al.
- Protection by 4th dose of BNT162b2 against Omicron in Israel. medRxiv. 2022.
- 446 30. Davies M-A, Kassanjee R, Rosseau P, Morden E, Johnson L, Solomon W, et al.
- Outcomes of laboratory-confirmed SARS-CoV-2 infection in the Omicron-driven fourth wave
- compared with previous waves in the Western Cape Province, South Africa. medRxiv. 2022.
- 449 31. Kahn F, Bonander C, Moghaddassi M, Rasmussen M, Malmqvist U, Inghammar M, et
- al. Risk of severe COVID-19 from the Delta and Omicron variants in relation to vaccination

- status, sex, age and comorbidities surveillance results from southern Sweden. medRxiv.
- 452 2022.
- 453 32. Feikin DR, Higdon MM, Abu-Raddad LJ, Andrews N, Araos R, Goldberg Y, et al.
- Duration of effectiveness of vaccines against SARS-CoV-2 infection and COVID-19 disease:
- results of a systematic review and meta-regression. The Lancet. 2022.
- 456 33. World Health Organization. Evaluation of COVID-19 vaccine effectiveness Interim
- 457 guidance https://www.who.int/publications/i/item/WHO-2019-nCoV-vaccine_effectiveness-
- 458 measurement-2021.12021 [updated March 17, 2021.
- 459 34. Jackson ML, Nelson JC. The test-negative design for estimating influenza vaccine
- 460 effectiveness. Vaccine. 2013;31(17):2165-8.
- 461 35. Klein NP, Stockwell MS, Demarco M, Gaglani M, Kharbanda AB, Irving SA, et al.
- 462 Effectiveness of COVID-19 Pfizer-BioNTech BNT162b2 mRNA Vaccination in Preventing
- 463 COVID-19-Associated Emergency Department and Urgent Care Encounters and
- 464 Hospitalizations Among Nonimmunocompromised Children and Adolescents Aged 5-17
- 465 Years VISION Network, 10 States, April 2021-January 2022. MMWR Morbidity and
- 466 mortality weekly report. 2022;71(9):352-8.
- 467 36. Fowlkes AL, Yoon SK, Lutrick K, Gwynn L, Burns J, Grant L, et al. Effectiveness of
- 468 2-Dose BNT162b2 (Pfizer BioNTech) mRNA Vaccine in Preventing SARS-CoV-2 Infection
- 469 Among Children Aged 5-11 Years and Adolescents Aged 12-15 Years PROTECT Cohort,
- July 2021-February 2022. MMWR Morbidity and mortality weekly report. 2022;71(11):422-
- 471 8.

472

Table 1: Effectiveness of COVID-19 vaccines against SARS-CoV-2 Omicron variant infection (infection (any type), symptomatic COVID-19, and severe COVID-19 (hospitalization, ICU admission, or death))

474 475

	Vaccine(s) used	Range of adjusted vaccine effectiveness (95% CI) ^{a,b,c}						
	for	≈14 days ^d	>14 days up to 3	>3 months up	>6 months			
	immunization		months	to 6 months				
Infection (any type)								
Full primary immunization	mRNA-based	16% (0–37) to	4.2% (-30.8–	-76.5% (-95.3– -	8.6% (3.3–			
	(any) ^e	55.2% (23.5–73.7);	29.8) to 42.8%	59.5) to 23%	13.6);			
		(7, 10, 14, 16, 18, 24)	(7, 14, 16)	(15.8–29.6); (7, 14)	(14)			
	Vector-based	-4% (-97–43) to	11.4% (NR to					
	(any) ^f	11.4 (NR to NR);	NR);					
		(16, 24)	(16)					
	Any vaccine ^h	-13% (-38–8) to	··	-38% (-61–-18);	-16% (-62–			
pri		62% (58–66);		(11)	17);			
		(11, 12, 21)			(11)			
도	Heterologous		••	••				
	schemeg	240/ (17.40)	54.60/ (20.4					
	mRNA-based	34% (16–49) to	54.6% (30.4–	••	••			
0 u	(any) ^e	66% (36–81);	70.4) ⁱ ;					
ati		$ \begin{array}{c ccccccccccccccccccccccccccccccccccc$	(7)					
niz	Vector-based	,						
mu	(any) ^f	••	••	••	••			
Booster immunization	Any vaccine ^h	38% (29–46) to						
er	7 my vaccine	76% (72–79);	••	••	••			
ost		$(16, 21, 24)^{i}$						
Bo	TT 4 1							
	Heterologous scheme ^j		••					
Sym	ptomatic COVID							
	mRNA-based	41% (-57–77) to	44.8% (16–63.8)	13.3% (12.0–	-9.4% (-16.3–			
tion	(any) ^e	76% (72–79);	to 54% (49–58);	14.7) to 20.8%	2.8) to 13%			
immunization	37	(8, 25, 26)	(8, 25)	(13.7-27.4);	(3–22);			
au				(8, 25)	(8, 25)			
l mu	Vector-based	6% (-103–56) to	35.7% (27.7–	6.1% (4.1–8.1);	-1.0% (-2.4–			
	(any) ^f	49.8% (40.7–57.5);	42.8); (8)	(8)	0.3);			
ary		(8, 26)			(8)			
im	Any vaccine ^h	36% (24-45);	12% (3-21);	15% (8 – 22);	2% (-17 – 17);			
pr		$(11)^k$	$(11)^k$	$(11)^k$	$(11)^{k}$			
Full primary	Heterologous							
<u> </u>	scheme ^g		10 -01					
Booster immunization	mRNA-based	50.0% (41.2–57.4)	`					
	(any) ^e	to 73.9% (73.2–	/					
		74.5);	(63.9–66.9);					
	Vector-based	$(6, 8, 9, 25)^{i}$	(8, 25)					
	vector-based (any) ^f	19% (-43–54); (26)		••	••			
	Any vaccine ^h	61% (56-65);						
	Any vaccine	(11) ^k	••	••				
	Heterologous	63.2% (62.6–63.8)	54.0% (53.3–					
Bo	scheme ^j	to 70.7% (70.1–	`		••			
		71.2);	(61.1–63.1); (8)					
		/,	(

		(8)							
Severe COVID-19 (hospitalization, ICU admission, or death)									
Full primary immunization	mRNA-based (any) ^e	3% (-114–56) to 81% (65–90); (8, 14, 15, 17, 19, 20, 25, 27, 28)	95% (57–99);	57.3% (42.7– 68.2) to 91% (31–99); (8, 20)	34.9% (17.7– 48.4) to 80.7% (71.3– 87); (8, 15, 17, 20, 25)				
	Vector-based (any) ^f	17% (-246–80) to 84% (-16–98); (20, 28)	21% (-81–66) to 85% (54–95); (20, 22)	-8% (-213–62) to 55.8% (34.1– 70.3); (8, 20)	32.7% (19.7– 43.6); (8)				
	Any vaccine ^h	55% (-106–90) to 77% (-91–97); (11, 23, 24)	37% (-71 – 77); (11)	75% (51-87); (11)	41 % (-22–72) to 86% (-12 – 98); (11, 23)				
	Heterologous scheme ^g								
Booster immunization	mRNA-based (any) ^e	12% (-45–46) to 100% (71.4–100); (6, 8, 11, 14, 15, 17, 19, 20, 25, 28) ⁱ	93.7% (80.3–98);		:				
	Vector-based (any) ^f	78% (76–80) to 84% (67–92); (20, 22)	79% (76–81) to 84% (80–88); (20)						
	Any vaccine ^h	60% (-163–90) to 956% (87-98); (11, 23, 24)							
Bo	Heterologous scheme ^j	86.9% (82.8–90.1) to 91.4% (86.8– 94.4); (8)	85% (81.2–88) to 91.2% (82.8– 95.5); (8)						

Footnotes:

477

483

487

496

- 478 ^a If not indicated otherwise, vaccine effectiveness (VE) estimates refer to the comparison of vaccinated 479 (2 or 3 doses, respectively) vs. unvaccinated;
- Provided VE estimates refer to the last reported time point per observation period (e.g. if studies reported VE after 2-4 and 5-9 weeks, the estimate of 5-9 weeks was included in the depicted effect range)
 - ^c Several effect ranges are derived from single studies providing data for different vaccine types
- 484 dtime point closest to 14 days
- 485 ° Comirnaty or Spikevax
- 486 ^f Vaxzevria or COVID-19-vaccine Janssen
 - g 1st dose with vector-based vaccine followed by prime booster dose of mRNA-based vaccine
- 488 h Studies include recipients of different vaccine types, and data was not further stratified
- 489 ⁱ Includes at least one study comparing booster vs. primary vaccination schedules (i.e., 3 vs. 2 doses)
- 490 j 1st dose with vector-based vaccine followed by prime booster dose, and 3rd dose of mRNA-based vaccine OR vector-based primary vaccination followed by one booster dose of mRNA-based vaccine
- 492 k One study estimated VE against vaccinated individuals who received second dose before ≥25 weeks,
- because of insufficient unvaccinated individuals available for analysis (13). VE against symptomatic infection with Omicron and Delta was estimated for 16-49 and 50+ year old's, respectively. Estimates
- are provided for all reported observation periods in supplement material 2

Figure 1. PRISMA flow chart

498






Figure 2. Forest plots of VE estimates against any type of SARS-CoV-2 infection of the Omicron variant after full primary immunization and booster dose, as reported in the study for the defined time strata after immunization. For booster immunization the COVID-19 vaccine used for primary immunization is indicated.



Notes: Full primary immunization with any vaccine (a), any mRNA-based vaccine (am), Comirnaty (c), or Vaxzeria (v);
*unadjusted estimates, calculated by the authors from data provided in the study; ¹ VE overall; ² VE in people previously infected with SARS-CoV-2; ³ VE estimates in people receiving the first dose of COVID-19 vaccine before SARS-CoV-2 infection was reported as 62% (CI 95%: 58-66); ⁴ VE in people not previously infected with SARS-CoV-2

Figure 3. Risk of Bias assessment for SARS-CoV-2 infection (any type) of the Omicron variant



501

502

503504

505

Figure 4. Forest plots of VE estimates against symptomatic COVID-19 due to SARS-CoV-2 infection of the Omicron variant after full primary immunization and booster dose, as reported in the study for the defined time strata after immunization. For booster immunization the COVID-19 vaccine used for primary immunization is indicated.




Figure 5. Risk of Bias assessment for symptomatic COVID-19 due to SARS-CoV-2 infection of the Omicron variant




Figure 6. Forest plots of VE estimates against severe COVID-19 (incl. hospitalization, ICU admission or death) due to SARS-CoV-2 infection of the Omicron variant after full primary immunization and booster dose, as reported in the study for the defined time strata after immunization. For booster immunization the COVID-19 vaccine used for primary immunization is indicated.




Figure 7. Risk of Bias assessment for severe COVID-19 (incl. hospitalization, ICU admission or death) due to SARS-CoV-2 infection of the Omicron variant



524

525